Jelena Klawitter
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 15 | 2025 | 235 | 4.390 |
Why?
| | Metabolomics | 21 | 2025 | 731 | 2.920 |
Why?
| | Kidney | 21 | 2025 | 1487 | 2.620 |
Why?
| | Tandem Mass Spectrometry | 17 | 2026 | 575 | 2.590 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 220 | 2.150 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 844 | 1.800 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 593 | 1.750 |
Why?
| | Oxidative Stress | 18 | 2020 | 1376 | 1.610 |
Why?
| | Cyclosporine | 10 | 2019 | 264 | 1.610 |
Why?
| | Metabolome | 9 | 2025 | 383 | 1.310 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 442 | 1.190 |
Why?
| | Sirolimus | 9 | 2019 | 282 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.030 |
Why?
| | Kidney Transplantation | 11 | 2025 | 696 | 1.020 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 599 | 1.010 |
Why?
| | Biomarkers | 23 | 2025 | 4258 | 0.970 |
Why?
| | Pravastatin | 4 | 2025 | 40 | 0.900 |
Why?
| | Energy Metabolism | 8 | 2022 | 942 | 0.900 |
Why?
| | Proteomics | 14 | 2020 | 1194 | 0.890 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 850 | 0.880 |
Why?
| | Allografts | 1 | 2025 | 151 | 0.870 |
Why?
| | Tryptophan | 5 | 2024 | 180 | 0.850 |
Why?
| | Tacrolimus | 5 | 2025 | 197 | 0.750 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 73 | 0.740 |
Why?
| | Endocannabinoids | 4 | 2025 | 57 | 0.740 |
Why?
| | Kynurenine | 5 | 2024 | 113 | 0.740 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2025 | 419 | 0.730 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 966 | 0.720 |
Why?
| | Lovastatin | 2 | 2013 | 36 | 0.710 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 572 | 0.680 |
Why?
| | Menopause | 3 | 2020 | 316 | 0.670 |
Why?
| | Arginine | 2 | 2024 | 267 | 0.660 |
Why?
| | Cannabinoids | 3 | 2024 | 180 | 0.650 |
Why?
| | Glomerular Filtration Rate | 11 | 2025 | 751 | 0.630 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 893 | 0.630 |
Why?
| | Mass Spectrometry | 10 | 2021 | 748 | 0.620 |
Why?
| | Myocardium | 2 | 2017 | 946 | 0.610 |
Why?
| | Kidney Failure, Chronic | 2 | 2025 | 596 | 0.610 |
Why?
| | Coronary Care Units | 1 | 2018 | 24 | 0.580 |
Why?
| | Adenosine | 3 | 2018 | 254 | 0.580 |
Why?
| | Signal Transduction | 11 | 2021 | 5256 | 0.570 |
Why?
| | Piperazines | 3 | 2009 | 394 | 0.560 |
Why?
| | Pyrimidines | 4 | 2014 | 537 | 0.540 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.530 |
Why?
| | Urine | 1 | 2017 | 62 | 0.520 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.510 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 144 | 0.500 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 120 | 0.490 |
Why?
| | Male | 54 | 2026 | 71757 | 0.490 |
Why?
| | Length of Stay | 4 | 2025 | 1314 | 0.480 |
Why?
| | Chromatography, Liquid | 9 | 2026 | 454 | 0.470 |
Why?
| | Animals | 42 | 2024 | 38231 | 0.470 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4578 | 0.470 |
Why?
| | Plasma | 1 | 2017 | 227 | 0.460 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 83 | 0.460 |
Why?
| | Female | 52 | 2026 | 77795 | 0.460 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 277 | 0.460 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.450 |
Why?
| | Humans | 75 | 2026 | 144228 | 0.440 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 316 | 0.440 |
Why?
| | Disease Progression | 8 | 2025 | 2874 | 0.430 |
Why?
| | Limit of Detection | 7 | 2024 | 97 | 0.420 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.410 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.410 |
Why?
| | Kidney Diseases | 4 | 2021 | 418 | 0.410 |
Why?
| | Dronabinol | 3 | 2026 | 249 | 0.400 |
Why?
| | Cell Proliferation | 4 | 2024 | 2541 | 0.400 |
Why?
| | Oxylipins | 2 | 2025 | 47 | 0.400 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 128 | 0.390 |
Why?
| | Inflammation | 9 | 2025 | 2900 | 0.380 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 7 | 0.380 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 30 | 0.380 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 71 | 0.370 |
Why?
| | Proteome | 3 | 2016 | 511 | 0.370 |
Why?
| | Oncogene Proteins | 1 | 2012 | 64 | 0.370 |
Why?
| | Dinoprost | 5 | 2019 | 50 | 0.360 |
Why?
| | Mutation | 2 | 2022 | 4120 | 0.360 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 858 | 0.350 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 272 | 0.350 |
Why?
| | Plant Extracts | 2 | 2024 | 194 | 0.340 |
Why?
| | Rats | 16 | 2024 | 5626 | 0.340 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 166 | 0.340 |
Why?
| | Nitric Oxide | 4 | 2024 | 903 | 0.330 |
Why?
| | Mitochondria | 1 | 2017 | 984 | 0.330 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 278 | 0.330 |
Why?
| | Postoperative Complications | 3 | 2021 | 2904 | 0.330 |
Why?
| | Purines | 2 | 2022 | 188 | 0.320 |
Why?
| | Blotting, Western | 6 | 2012 | 1207 | 0.310 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 626 | 0.310 |
Why?
| | Hypoxia | 6 | 2024 | 1202 | 0.300 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 358 | 0.300 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 467 | 0.300 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 6043 | 0.300 |
Why?
| | Prostaglandins | 3 | 2022 | 95 | 0.300 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 62 | 0.290 |
Why?
| | Theophylline | 2 | 2020 | 41 | 0.290 |
Why?
| | Autophagy | 3 | 2024 | 288 | 0.290 |
Why?
| | Glycolysis | 4 | 2012 | 342 | 0.290 |
Why?
| | Mice | 19 | 2024 | 18471 | 0.280 |
Why?
| | Infant | 10 | 2025 | 9911 | 0.280 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 17 | 0.280 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 20 | 0.280 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2223 | 0.280 |
Why?
| | Mice, Knockout | 7 | 2023 | 3124 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3620 | 0.270 |
Why?
| | Vascular Diseases | 2 | 2021 | 251 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2024 | 3618 | 0.260 |
Why?
| | Amino Acids | 2 | 2025 | 519 | 0.260 |
Why?
| | Blood Vessels | 2 | 2019 | 173 | 0.260 |
Why?
| | Prospective Studies | 13 | 2025 | 7911 | 0.250 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3402 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 898 | 0.250 |
Why?
| | Time Factors | 8 | 2022 | 7081 | 0.250 |
Why?
| | Infant, Newborn | 8 | 2025 | 6380 | 0.240 |
Why?
| | Rats, Wistar | 6 | 2018 | 460 | 0.240 |
Why?
| | Microsomes, Liver | 2 | 2019 | 84 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2024 | 54 | 0.230 |
Why?
| | Child | 10 | 2025 | 22493 | 0.230 |
Why?
| | Swine | 3 | 2022 | 843 | 0.220 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 76 | 0.220 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.220 |
Why?
| | Treatment Outcome | 9 | 2025 | 11501 | 0.220 |
Why?
| | Alkaloids | 1 | 2024 | 28 | 0.220 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 69 | 0.220 |
Why?
| | Mitragyna | 1 | 2024 | 8 | 0.220 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2502 | 0.220 |
Why?
| | Young Adult | 12 | 2023 | 13949 | 0.220 |
Why?
| | Adult | 19 | 2026 | 40230 | 0.210 |
Why?
| | Transplantation, Homologous | 1 | 2025 | 414 | 0.210 |
Why?
| | Adolescent | 10 | 2025 | 22282 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 18 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 48 | 0.200 |
Why?
| | Citrulline | 1 | 2024 | 46 | 0.200 |
Why?
| | Graft Rejection | 4 | 2017 | 537 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 41 | 0.190 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 26 | 0.190 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 111 | 0.190 |
Why?
| | Analgesia | 1 | 2024 | 102 | 0.190 |
Why?
| | Tissue Distribution | 2 | 2014 | 328 | 0.190 |
Why?
| | Cytokines | 5 | 2025 | 2098 | 0.190 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 27 | 0.180 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 589 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.180 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 114 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 511 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 12 | 0.180 |
Why?
| | Double-Blind Method | 6 | 2025 | 2023 | 0.180 |
Why?
| | Curcumin | 1 | 2021 | 26 | 0.170 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 306 | 0.170 |
Why?
| | Fetal Diseases | 1 | 2023 | 191 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 462 | 0.170 |
Why?
| | Middle Aged | 17 | 2025 | 35731 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 482 | 0.170 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 79 | 0.170 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 105 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 47 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 156 | 0.170 |
Why?
| | Niacinamide | 1 | 2021 | 86 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2022 | 249 | 0.160 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.160 |
Why?
| | Methionine | 1 | 2021 | 163 | 0.160 |
Why?
| | Organ Size | 2 | 2025 | 471 | 0.160 |
Why?
| | Benzamides | 3 | 2009 | 225 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 413 | 0.160 |
Why?
| | Nephrectomy | 1 | 2021 | 156 | 0.160 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 46 | 0.160 |
Why?
| | Cannabidiol | 1 | 2022 | 135 | 0.150 |
Why?
| | Pain | 1 | 2025 | 777 | 0.150 |
Why?
| | Vasodilation | 3 | 2018 | 521 | 0.150 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 95 | 0.150 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 18 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 27 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 87 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 303 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 35 | 0.140 |
Why?
| | Vitamin D | 2 | 2019 | 402 | 0.140 |
Why?
| | Brain | 2 | 2013 | 2909 | 0.140 |
Why?
| | Blood Proteins | 1 | 2020 | 250 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 151 | 0.140 |
Why?
| | Glucose | 2 | 2017 | 1044 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 56 | 0.140 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2020 | 186 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 337 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 433 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 265 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 46 | 0.130 |
Why?
| | Phenotype | 3 | 2022 | 3185 | 0.130 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 49 | 0.130 |
Why?
| | Therapies, Investigational | 1 | 2017 | 18 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
| | Phenylpropionates | 1 | 2017 | 27 | 0.130 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.130 |
Why?
| | Complement Factor B | 1 | 2018 | 106 | 0.130 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.130 |
Why?
| | Endothelins | 1 | 2017 | 64 | 0.130 |
Why?
| | Sex Characteristics | 2 | 2013 | 786 | 0.130 |
Why?
| | Pyridazines | 1 | 2017 | 58 | 0.130 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 128 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 315 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 95 | 0.130 |
Why?
| | Cell Cycle | 2 | 2011 | 632 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 80 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 145 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 192 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 753 | 0.130 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 55 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 179 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 2018 | 288 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2018 | 252 | 0.120 |
Why?
| | Brachial Artery | 4 | 2019 | 207 | 0.120 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 69 | 0.120 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 364 | 0.120 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.120 |
Why?
| | Breast | 1 | 2017 | 162 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1171 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 90 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 25 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 132 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 239 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 180 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 5 | 0.120 |
Why?
| | Linoleic Acids | 1 | 2015 | 6 | 0.120 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 35 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Enzyme Activation | 1 | 2017 | 782 | 0.110 |
Why?
| | Premature Birth | 1 | 2019 | 381 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2097 | 0.110 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 31 | 0.110 |
Why?
| | Fishes | 1 | 2016 | 110 | 0.110 |
Why?
| | Postoperative Period | 1 | 2016 | 353 | 0.110 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 517 | 0.110 |
Why?
| | Reperfusion Injury | 1 | 2018 | 297 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 423 | 0.110 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 38 | 0.110 |
Why?
| | Aerosols | 1 | 2016 | 185 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 141 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 648 | 0.110 |
Why?
| | Serine | 1 | 2015 | 138 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.100 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 373 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 170 | 0.100 |
Why?
| | Child, Preschool | 3 | 2025 | 11656 | 0.100 |
Why?
| | DNA Methylation | 1 | 2019 | 676 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 978 | 0.100 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 458 | 0.100 |
Why?
| | Tidal Volume | 1 | 2014 | 112 | 0.100 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 22 | 0.100 |
Why?
| | Cannabis | 1 | 2021 | 518 | 0.100 |
Why?
| | Cattle | 1 | 2016 | 1005 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 320 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1309 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 112 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 342 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 105 | 0.100 |
Why?
| | Respiration, Artificial | 2 | 2018 | 709 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1972 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2081 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 388 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 646 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2413 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4159 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 57 | 0.100 |
Why?
| | Pilot Projects | 4 | 2023 | 1858 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 55 | 0.100 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 15 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.090 |
Why?
| | Ion Transport | 1 | 2012 | 63 | 0.090 |
Why?
| | K562 Cells | 2 | 2009 | 94 | 0.090 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.090 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 109 | 0.090 |
Why?
| | Integrins | 1 | 2012 | 90 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5776 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 136 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1003 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2930 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 187 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 179 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 647 | 0.090 |
Why?
| | Endothelial Cells | 2 | 2018 | 864 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 227 | 0.090 |
Why?
| | Administration, Oral | 3 | 2026 | 842 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 197 | 0.090 |
Why?
| | Fatty Acids | 1 | 2014 | 450 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 203 | 0.080 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.080 |
Why?
| | Models, Animal | 1 | 2013 | 394 | 0.080 |
Why?
| | Aged | 7 | 2025 | 25675 | 0.080 |
Why?
| | Artifacts | 1 | 2011 | 140 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 293 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1110 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 786 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 59 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 27 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 135 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 377 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 179 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1193 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 102 | 0.080 |
Why?
| | Drug Approval | 1 | 2010 | 88 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 355 | 0.080 |
Why?
| | Heart Ventricles | 2 | 2024 | 754 | 0.070 |
Why?
| | Reference Standards | 1 | 2009 | 181 | 0.070 |
Why?
| | Risk Assessment | 1 | 2018 | 3560 | 0.070 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 48 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2013 | 4172 | 0.070 |
Why?
| | Oncogenes | 1 | 2009 | 121 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1826 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 132 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1986 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 310 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 596 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 581 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1762 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 218 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 211 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 305 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 168 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2450 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 524 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 547 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 669 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 394 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 178 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 126 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1241 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 48 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1128 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 245 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 539 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 422 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2198 | 0.060 |
Why?
| | Renal Circulation | 1 | 2025 | 75 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 453 | 0.060 |
Why?
| | Kynurenic Acid | 1 | 2024 | 18 | 0.050 |
Why?
| | Isomerism | 1 | 2024 | 55 | 0.050 |
Why?
| | Blood Pressure | 3 | 2019 | 1752 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1950 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2008 | 396 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10641 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3061 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 1916 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.050 |
Why?
| | Palliative Care | 2 | 2024 | 986 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1225 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 89 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 139 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2025 | 251 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3087 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 322 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 55 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Androstanols | 1 | 2022 | 23 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 57 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1032 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 81 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 399 | 0.040 |
Why?
| | Steroids | 1 | 2022 | 161 | 0.040 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 34 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2909 | 0.040 |
Why?
| | Nitriles | 1 | 2022 | 205 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 138 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 104 | 0.040 |
Why?
| | Pregnancy | 3 | 2019 | 7180 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 165 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 77 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 87 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 63 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 165 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 32 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 24 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 216 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5876 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 145 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 139 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 155 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 297 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1270 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 14 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 499 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 79 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 105 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1270 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 93 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 162 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 807 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 492 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 188 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 38 | 0.030 |
Why?
| | Complement C5a | 1 | 2018 | 54 | 0.030 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2018 | 24 | 0.030 |
Why?
| | Rewarming | 1 | 2018 | 21 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 83 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2185 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 188 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 203 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 524 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1692 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 187 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 150 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 1072 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 531 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 310 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 391 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 311 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 65 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 145 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1098 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 225 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 351 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 37 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2032 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 612 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 491 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 144 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 692 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 399 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Safety | 1 | 2017 | 352 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 318 | 0.030 |
Why?
| | Larva | 1 | 2016 | 241 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 248 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 20 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 32 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 1003 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 408 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 592 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 89 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 322 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 902 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1625 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 66 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 61 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4221 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 99 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 13 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 134 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1515 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1313 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 114 | 0.030 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 43 | 0.020 |
Why?
| | Orchiectomy | 1 | 2013 | 76 | 0.020 |
Why?
| | Altitude | 1 | 2017 | 474 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 324 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2015 | 509 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 54 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 43 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 173 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 190 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 715 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 75 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 21 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 154 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 199 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 177 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1826 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1116 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 242 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 204 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 145 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 608 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 586 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 80 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 84 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 700 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 243 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2269 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 291 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1496 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 202 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 2 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 645 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 23 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 514 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 673 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 873 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 400 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 406 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 57 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 174 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 112 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 22 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2446 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 392 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1361 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 370 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1836 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 8 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 832 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 201 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 90 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 131 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 16805 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 170 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 143 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2533 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 907 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1848 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 445 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 345 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 992 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2149 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1839 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2914 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2955 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4591 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1639 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 419 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2630 | 0.010 |
Why?
| | United States | 1 | 2010 | 15641 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|